Topics in Companion Animal Medicine
Volume 24, Issue 3 , Pages 151-156 , August 2009

Intravenous Aminobisphosphonates for Managing Complications of Malignant Osteolysis in Companion Animals

  • Timothy M. Fan, DVM, PhD, DACVIM

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Timothy M. Fan, DVM, PhD, DACVIM, 1008 West Hazelwood Dr, Urbana, IL 61802

References 

  1. Grill V, Ho P, Body JJ, et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab. 1991;73(6):1309–1315
  2. Michael WR, King WR, Wakim JM. Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicol Appl Pharmacol. 1972;21(4):503–515
  3. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18(2):75–85
  4. Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol. 2004;44(9):951–965
  5. Kasting GB, Francis MD. Retention of etidronate in human, dog, and rat. J Bone Miner Res. 1992;7(5):513–522
  6. Lin JH, Chen IW, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos. 1992;20(4):473–478
  7. Lin JH, Chen IW, Deluna FA, et al. Renal handling of alendronate in rats (An uncharacterized renal transport system). Drug Metab Dispos. 1992;20(4):608–613
  8. Lin JH, Duggan DE, Chen IW, et al. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos. 1991;19(5):926–932
  9. Marks SC, Walker DG. The hematogenous origin of osteoclasts: experimental evidence from osteopetrotic (microphthalmic) mice treated with spleen cells from beige mouse donors. Am J Anat. 1981;161(1):1–10
  10. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10(10):1478–1487
  11. Selander KS, Monkkonen J, Karhukorpi EK, et al. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol. 1996;50(5):1127–1138
  12. Abraham SC, Cruz-Correa M, Lee LA, et al. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol. 1999;12(12):1152–1157
  13. Adami S, Zamberlan N. Adverse effects of bisphosphonates (A comparative review). Drug Saf. 1996;14(3):158–170
  14. Body JJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol. 2001;28(4 Suppl 11):49–53
  15. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335(14):1016–1021
  16. Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. Oncologist. 2005;10(Suppl 1):3–7
  17. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64(1):281–289
  18. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12(6):1164–1172
  19. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17(6):897–907
  20. Wahner HW, Dunn WL, Riggs BL. Assessment of bone mineral (Part 2). J Nucl Med. 1984;25(11):1241–1253
  21. Wahner HW, Dunn WL, Riggs BL. Assessment of bone mineral (Part 1). J Nucl Med. 1984;25(10):1134–1141
  22. Frank JA, Ling A, Patronas NJ, et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. AJR Am J Roentgenol. 1990;155(5):1043–1048
  23. Shapiro CL, Keating J, Angell JE, et al. Monitoring therapeutic response in skeletal metastases using dual-energy x-ray absorptiometry: a prospective feasibility study in breast cancer patients. Cancer Invest. 1999;17(8):566–574
  24. Berruti A, Dogliotti L, Osella G, et al. Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment. Oncol Rep. 2000;7(4):777–781
  25. Smith GL, Doherty AP, Banks LM, et al. Dual x-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients. Clin Exp Metastasis. 2000;18(5):385–390
  26. Koeberle D, Bacchus L, Thuerlimann B, et al. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. Support Care Cancer. 1999;7(1):21–27
  27. Fan TM, de Lorimier LP, Charney SC, et al. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med. 2005;19(1):74–80
  28. Fan TM, de Lorimier LP, Garrett LD, et al. The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis. J Vet Intern Med. 2008;22(2):380–387
  29. Fan TM, de Lorimier LP, O'Dell-Anderson K, et al. Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain. J Vet Intern Med. 2007;21(3):431–439
  30. Clamp A, Danson S, Nguyen H, et al. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol. 2004;5(10):607–616
  31. Koizumi M, Yonese J, Fukui I, et al. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J Urol. 2002;167(4):1863–1866
  32. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer. 2000;88(Suppl 12):2919–2926
  33. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer. 1998;34(13):2021–2026
  34. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol. 2002;20(3):850–856
  35. Hanson DA, Weis MA, Bollen AM, et al. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 1992;7(11):1251–1258
  36. Worsfold M, Powell DE, Jones TJ, et al. Assessment of urinary bone markers for monitoring treatment of osteoporosis. Clin Chem. 2004;50(12):2263–2270
  37. Lucas PW, Fan TM, Garrett LD, et al. A comparison of five different bone resorption markers in osteosarcoma-bearing dogs, normal dogs, and dogs with orthopedic diseases. J Vet Intern Med. 2008;22(4):1008–1013
  38. Wypij JM, Fan TM, Fredrickson RL, et al. In vivo and in vitro efficacy of zoledronate for treating oral squamous cell carcinoma in cats. J Vet Intern Med. 2008;22(1):158–163
  39. Fan TM, Charney SC, de Lorimier LP, et al. Double-blind placebo-controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous Doxorubicin for canine appendicular osteosarcoma bone pain. J Vet Intern Med. 2009;23(1):152–160
  40. Ferretti G, Fabi A, Carlini P, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology. 2005;69(1):35–43
  41. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003;9(8):2893–2897
  42. Vincenzi B, Santini D, Dicuonzo G, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res. 2005;25(3):144–151
  43. de Lorimier LP, Fan TM. Bone metabolic effects of single-dose zoledronate in healthy dogs. J Vet Intern Med. 2005;19(6):924–927
  44. Hostutler RA, Chew DJ, Jaeger JQ, et al. Uses and effectiveness of pamidronate disodium for treatment of dogs and cats with hypercalcemia. J Vet Intern Med. 2005;19(1):29–33
  45. Kadar E, Rush JE, Wetmore L, et al. Electrolyte disturbances and cardiac arrhythmias in a dog following pamidronate, calcitonin, and furosemide administration for hypercalcemia of malignancy. J Am Anim Hosp Assoc. 2004;40(1):75–81

PII: S1938-9736(09)00014-2

doi: 10.1053/j.tcam.2009.02.003

Topics in Companion Animal Medicine
Volume 24, Issue 3 , Pages 151-156 , August 2009

Article Tools